Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
20.75
+0.55 (2.72%)
Aug 21, 2025, 4:00 PM - Market closed
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts that cover Arrowhead Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $43.14, which forecasts a 107.90% increase in the stock price over the next year. The lowest target is $17 and the highest is $80.
Price Target: $43.14 (+107.90%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arrowhead Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 4 | 4 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 10 | 10 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +189.16% | Aug 11, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $40 → $38 | Buy | Maintains | $40 → $38 | +83.13% | Aug 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +285.54% | May 20, 2025 |
| Citigroup | Citigroup | Hold Maintains $21 → $17 | Hold | Maintains | $21 → $17 | -18.07% | May 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +189.16% | May 13, 2025 |
Financial Forecast
Revenue This Year
798.44M
from 3.55M
Increased by 22,384.93%
Revenue Next Year
319.07M
from 798.44M
Decreased by -60.04%
EPS This Year
0.04
from -5.00
EPS Next Year
-3.43
from 0.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 960.2M | 490.3M | 564.0M | ||
| Avg | 798.4M | 319.1M | 373.3M | ||
| Low | 652.0M | 157.8M | 262.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26,941.1% | -38.6% | 76.8% | ||
| Avg | 22,384.9% | -60.0% | 17.0% | ||
| Low | 18,261.6% | -80.2% | -17.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.65 | -1.74 | -0.71 | ||
| Avg | 0.04 | -3.43 | -3.68 | ||
| Low | -1.24 | -4.63 | -5.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.